Sales of all major liver cancer treatments are on the decline.

Sales of Nexavar (sorafenib), which had dominated the first-line treatment market for liver cancer for over a decade, is on a continuous decline since the entry of its generics, and sales of Nexavar’s main competitor Lenvima have also been shown to be slowing down recently.

The industry expects the sales of Nexavar and Lenvima to fall further with the reimbursement applied to the Tecentriq+Avastin combination therapy as first-line treatment for liver cancer in Q2 this year.

◆Nexavar’s quarterly sales fall below ₩2 billion…affected by the entry of competitor drug and generics

Kim, Jin-Gu(kjg@dailypharm.com)